SlideShare a Scribd company logo
1 of 27
Fever
National Pediatric Nighttime Curriculum
Written by Debbie Sakai, M.D.
Institution: Lucile Packard Children’s Hospital
Case 1
 4-month-old well-appearing girl admitted
for croup and respiratory distress.
Develops fever to 39.1.
What additional evaluation would you do at
this point?
Case 2
 12-year old boy with AML, in induction,
admitted for febrile neutropenia. He
had just received his first dose of
ceftazidime and vancomycin when he
developed another fever to 38.5, chills,
and new dizziness shortly after
receiving the antibiotics.
What would be the next steps in this
patient’s management?
Objectives
 To determine which patients are at high
risk of developing sepsis.
 To assess patient with fever.
 To initiate empiric therapy.
Objectives
 To determine which patients are at high
risk of developing sepsis.
 To assess patient with fever.
 To initiate empiric therapy.
Which patients are high-risk for
sepsis?
 Neonates
 Transplant recipients
Bone marrow
Solid organ
 Oncology patients
Undergoing therapy, mucositis, central line
Most chemotherapy: nadir ~ 10 days after rx
 Asplenic patients, including sickle cell
Definition of fever
 38.0
 Neonates (< 12 months)
 Any immunocompromised patient
 Including transplant patients, patients with
immunodeficiencies, oncology patients (sustained ≥38 x 1
hour)
 38.5
 All other patients
 These are general guidelines, individual
patients/services may have different parameters
What etiologies cause fever?
 Infectious
 Inflammatory
 Oncologic
 Other: CNS dysfunction, drug fever
 Life-threatening conditions
Infectious
 Systemic
 Bacteremia, sepsis, meningitis, endocarditis
 Respiratory
 URI, sinusitis, otitis media, pharyngitis, pneumonia,
bronchiolitis
 Abdominal
 Urinary tract infection, abscess (liver, kidney, pelvis)
 Bone/joint infection
 Hardware infection
 Central line, VP shunt, G-tube
Inflammatory
 Kawasaki disease
 Juvenile inflammatory arthritis
 Lupus
 Inflammatory bowel disease
 Henoch-Schonlein purpura
Others
 CNS dysfunction
 Drug fever
Life-threatening conditions
 Sepsis, febrile neutropenia
 Vital sign instability, poor-perfusion, may have altered mental
status, disseminated intravascular coagulation
 Hemophagocytic lymphohistiocytosis
 Splenomegaly, bicytopenia, elevated ferritin, elevated
triglycerides, low fibrinogen, hemophagocytosis, low/absent NK
cell function, elevated soluble IL2 receptor
 Malignant hyperthermia
 Following administration of inhaled anesthetics or depolarizing
neuromuscular blockers (succinylcholine), at-risk patients
include those with myopathy
 Muscle rigidity, rhabdomyolysis, acidosis, tachycardia
Objectives
 To determine which patients are at high
risk of developing sepsis.
 To assess patient with fever.
 To initiate empiric therapy.
Assessment
 Vital signs
 Repeat physical exam
 Overall appearance (sick, toxic)
 Central/peripheral lines
 Incisions/wounds
 VP shunt/tracheostomy/gastrostomy tube
 Oral mucosa/perineal area for neutropenic patients
 Perfusion
 Call for help if concerning vital signs/exam
 Fellow or attending
 Rapid response team (RRT)/PICU
Laboratory evaluation
 What would you do if the patient has
hardware (VP shunt, tracheostomy,
gastrostomy tube) or central line?
CBC with differential
Blood culture
CSF (tap VP shunt)
Laboratory evaluation
 What would you do if the patient has a
high risk for sepsis?
Immunocompromised
Transplant recipient
Oncology patient
CBC with differential
Blood culture
Urinalysis and urine culture
Laboratory evaluation
 What would you do for an infant ≤ 2
months of age?
CBC with differential
Blood culture
Catheterized urinalysis and urine culture
Lumbar puncture
Laboratory evaluation
 Who needs a urinalysis and urine culture?
Circumcised males < 6 months
Uncircumcised males < 1 year
Females < 2 years
Immunocompromised patients
Patients with history of UTI/pyelonephritis
Laboratory evaluation
 Who needs a lumbar puncture?
 Neonates ≤ 2 months
 Ill-appearing
 Altered mental status
 What tests do you send?
 Gram stain and culture
 Cell count and differential
 Protein and glucose
 Extra tube for additional studies
 Enteroviral PCR, HSV PCR, CA encephalitis project
Laboratory evaluation
 Consider CRP, ESR
 Consider PT/PTT, fibrinogen
 Consider chest x-ray
 Consider nasopharyngeal DFA
 For immunosuppressed patients consider:
Viral PCR studies (ie CMV, EBV, HHV6)
Additional imaging (ie ultrasound, CT scan)
Objectives
 To determine which patients are at high
risk of developing sepsis.
 To assess patient with fever.
 To initiate empiric therapy.
Treatment for non-high risk patients
 May not need empiric antibiotics
 Consider the following issues:
Is patient clinically stable?
Are the screening laboratory studies
suggestive of infection?
Treatment for patients with central
lines
 Ceftriaxone
 Vancomycin
Treatment for neonates ≤ 2 months
 If < 28 days old
Ampicillin AND cefotaxime OR
Ampicillin AND gentamicin
 Consider acyclovir
 If 29-60 days old
Ceftriaxone ± Ampicillin OR Vancomycin
Until CSF results are known (cell count,
protein, glucose), initiate therapy with
meningitic dosing regimen
Treatment for febrile neutropenia
 Broad-spectrum antibiotics with Pseudomonas
coverage
 Ex: use ceftazidime or piperacillin-tazobactam
 Consider double coverage for possible resistant
Pseudomonas
 Ex: add amikacin or tobramycin
 Consider gram-positive coverage (central line,
skin infections)
 Ex: add vancomycin
 Consider anaerobic coverage (mucositis,
typhlitis)
 Ex: use piperacillin-tazobactam or add clindamycin
Take home points
 Infections are the most common cause of fever
in children
 During assessment of a child with fever, pay
close attention to vital sign changes, overall
appearance, and potential sites of infection
 Closely monitor for clinical decompensation after
antibiotic administration, particularly in patients
at high-risk of developing sepsis
References
 Baraff LJ. Management of fever without source in infants and
children. Ann Emerg Med. 2000. 36:602-14.
 Meckler G, Lindemulder S. Fever and neutropenia in pediatric
patients with cancer. Emerg Med Clin N Am. 2009. 27:525-44.
 Palazzi EL. Approach to the child with fever of unknown origin.
UpToDate. 2011
 Palazzi DL. Etiologies of fever of unknown origin. UpToDate.
2011.
 Tolan R. Fever of unknown origin: A diagnostic approach to this
vexing problem. Clin Pediatr. 2010;49:207-13.

More Related Content

Similar to fever-presentation (1).ppt

Neonatal sepsis kinara
Neonatal sepsis kinaraNeonatal sepsis kinara
Neonatal sepsis kinaraKinara Kenyoru
 
Case presentation Urosepsis
Case presentation UrosepsisCase presentation Urosepsis
Case presentation Urosepsistbf413
 
Febrile neutropenia - Infections in cancer patients
Febrile neutropenia - Infections in cancer patientsFebrile neutropenia - Infections in cancer patients
Febrile neutropenia - Infections in cancer patientsAli Musavi
 
National guidelines on pediatric TB
National guidelines on pediatric TBNational guidelines on pediatric TB
National guidelines on pediatric TBAbhijeet Deshmukh
 
Mod 6 case 2022
Mod 6 case 2022Mod 6 case 2022
Mod 6 case 2022vetindex4
 
UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...
UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...
UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...intensivecaresociety
 
Chapter 30 febrile neutropenia
Chapter 30 febrile neutropeniaChapter 30 febrile neutropenia
Chapter 30 febrile neutropeniaNilesh Kucha
 
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Gamal Agmy
 
Community acquired pneumonia
Community acquired pneumoniaCommunity acquired pneumonia
Community acquired pneumoniaHarsha Vardhan
 
Case Presentation MAI
Case Presentation MAICase Presentation MAI
Case Presentation MAIJoseph Helms
 
Pediatric community Acquired Pneumonia
Pediatric community Acquired Pneumonia Pediatric community Acquired Pneumonia
Pediatric community Acquired Pneumonia NITISH SHAH
 
Lymphadenopathy in children
Lymphadenopathy in children Lymphadenopathy in children
Lymphadenopathy in children Pediatrics
 
20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptxShamiPokhrel2
 
20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptxShamiPokhrel2
 

Similar to fever-presentation (1).ppt (20)

Neonatal sepsis kinara
Neonatal sepsis kinaraNeonatal sepsis kinara
Neonatal sepsis kinara
 
Fever infants
Fever infantsFever infants
Fever infants
 
Case presentation Urosepsis
Case presentation UrosepsisCase presentation Urosepsis
Case presentation Urosepsis
 
Febrile neutropenia - Infections in cancer patients
Febrile neutropenia - Infections in cancer patientsFebrile neutropenia - Infections in cancer patients
Febrile neutropenia - Infections in cancer patients
 
National guidelines on pediatric TB
National guidelines on pediatric TBNational guidelines on pediatric TB
National guidelines on pediatric TB
 
Mod 6 case 2022
Mod 6 case 2022Mod 6 case 2022
Mod 6 case 2022
 
Febrile neutropaenia
Febrile neutropaeniaFebrile neutropaenia
Febrile neutropaenia
 
Febrile neutropenia
Febrile neutropeniaFebrile neutropenia
Febrile neutropenia
 
UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...
UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...
UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...
 
Chapter 30 febrile neutropenia
Chapter 30 febrile neutropeniaChapter 30 febrile neutropenia
Chapter 30 febrile neutropenia
 
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
 
Community acquired pneumonia
Community acquired pneumoniaCommunity acquired pneumonia
Community acquired pneumonia
 
Case Presentation MAI
Case Presentation MAICase Presentation MAI
Case Presentation MAI
 
Pediatric community Acquired Pneumonia
Pediatric community Acquired Pneumonia Pediatric community Acquired Pneumonia
Pediatric community Acquired Pneumonia
 
Lymphadenopathy in children
Lymphadenopathy in children Lymphadenopathy in children
Lymphadenopathy in children
 
HAP
HAPHAP
HAP
 
Sepsis
SepsisSepsis
Sepsis
 
20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx
 
20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx
 
Emergencies in oncology
Emergencies in oncologyEmergencies in oncology
Emergencies in oncology
 

More from Kiramat2

02 Epilepsy in children.pptx
02 Epilepsy in children.pptx02 Epilepsy in children.pptx
02 Epilepsy in children.pptxKiramat2
 
THYROID DISEASES FOR STUDENTS king saud.ppt
THYROID DISEASES FOR STUDENTS king saud.pptTHYROID DISEASES FOR STUDENTS king saud.ppt
THYROID DISEASES FOR STUDENTS king saud.pptKiramat2
 
08_pediatric_leukemias.ppt
08_pediatric_leukemias.ppt08_pediatric_leukemias.ppt
08_pediatric_leukemias.pptKiramat2
 
neonatal hypoglycemia transient.pdf
neonatal hypoglycemia transient.pdfneonatal hypoglycemia transient.pdf
neonatal hypoglycemia transient.pdfKiramat2
 
fever-presentation.ppt
fever-presentation.pptfever-presentation.ppt
fever-presentation.pptKiramat2
 

More from Kiramat2 (6)

02 Epilepsy in children.pptx
02 Epilepsy in children.pptx02 Epilepsy in children.pptx
02 Epilepsy in children.pptx
 
THYROID DISEASES FOR STUDENTS king saud.ppt
THYROID DISEASES FOR STUDENTS king saud.pptTHYROID DISEASES FOR STUDENTS king saud.ppt
THYROID DISEASES FOR STUDENTS king saud.ppt
 
08_pediatric_leukemias.ppt
08_pediatric_leukemias.ppt08_pediatric_leukemias.ppt
08_pediatric_leukemias.ppt
 
neonatal hypoglycemia transient.pdf
neonatal hypoglycemia transient.pdfneonatal hypoglycemia transient.pdf
neonatal hypoglycemia transient.pdf
 
CMPA.pdf
CMPA.pdfCMPA.pdf
CMPA.pdf
 
fever-presentation.ppt
fever-presentation.pptfever-presentation.ppt
fever-presentation.ppt
 

Recently uploaded

How to Add a Tool Tip to a Field in Odoo 17
How to Add a Tool Tip to a Field in Odoo 17How to Add a Tool Tip to a Field in Odoo 17
How to Add a Tool Tip to a Field in Odoo 17Celine George
 
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxCOMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxannathomasp01
 
Simple, Complex, and Compound Sentences Exercises.pdf
Simple, Complex, and Compound Sentences Exercises.pdfSimple, Complex, and Compound Sentences Exercises.pdf
Simple, Complex, and Compound Sentences Exercises.pdfstareducators107
 
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptxExploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptxPooja Bhuva
 
21st_Century_Skills_Framework_Final_Presentation_2.pptx
21st_Century_Skills_Framework_Final_Presentation_2.pptx21st_Century_Skills_Framework_Final_Presentation_2.pptx
21st_Century_Skills_Framework_Final_Presentation_2.pptxJoelynRubio1
 
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxHMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxmarlenawright1
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and ModificationsMJDuyan
 
How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17Celine George
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17Celine George
 
Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...
Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...
Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...EADTU
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxheathfieldcps1
 
How to Manage Call for Tendor in Odoo 17
How to Manage Call for Tendor in Odoo 17How to Manage Call for Tendor in Odoo 17
How to Manage Call for Tendor in Odoo 17Celine George
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...Nguyen Thanh Tu Collection
 
FICTIONAL SALESMAN/SALESMAN SNSW 2024.pdf
FICTIONAL SALESMAN/SALESMAN SNSW 2024.pdfFICTIONAL SALESMAN/SALESMAN SNSW 2024.pdf
FICTIONAL SALESMAN/SALESMAN SNSW 2024.pdfPondicherry University
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxEsquimalt MFRC
 
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Pooja Bhuva
 
Economic Importance Of Fungi In Food Additives
Economic Importance Of Fungi In Food AdditivesEconomic Importance Of Fungi In Food Additives
Economic Importance Of Fungi In Food AdditivesSHIVANANDaRV
 
Details on CBSE Compartment Exam.pptx1111
Details on CBSE Compartment Exam.pptx1111Details on CBSE Compartment Exam.pptx1111
Details on CBSE Compartment Exam.pptx1111GangaMaiya1
 

Recently uploaded (20)

How to Add a Tool Tip to a Field in Odoo 17
How to Add a Tool Tip to a Field in Odoo 17How to Add a Tool Tip to a Field in Odoo 17
How to Add a Tool Tip to a Field in Odoo 17
 
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxCOMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
 
Simple, Complex, and Compound Sentences Exercises.pdf
Simple, Complex, and Compound Sentences Exercises.pdfSimple, Complex, and Compound Sentences Exercises.pdf
Simple, Complex, and Compound Sentences Exercises.pdf
 
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptxExploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
 
21st_Century_Skills_Framework_Final_Presentation_2.pptx
21st_Century_Skills_Framework_Final_Presentation_2.pptx21st_Century_Skills_Framework_Final_Presentation_2.pptx
21st_Century_Skills_Framework_Final_Presentation_2.pptx
 
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxHMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 
OS-operating systems- ch05 (CPU Scheduling) ...
OS-operating systems- ch05 (CPU Scheduling) ...OS-operating systems- ch05 (CPU Scheduling) ...
OS-operating systems- ch05 (CPU Scheduling) ...
 
Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...
Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...
Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
How to Manage Call for Tendor in Odoo 17
How to Manage Call for Tendor in Odoo 17How to Manage Call for Tendor in Odoo 17
How to Manage Call for Tendor in Odoo 17
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
FICTIONAL SALESMAN/SALESMAN SNSW 2024.pdf
FICTIONAL SALESMAN/SALESMAN SNSW 2024.pdfFICTIONAL SALESMAN/SALESMAN SNSW 2024.pdf
FICTIONAL SALESMAN/SALESMAN SNSW 2024.pdf
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
Our Environment Class 10 Science Notes pdf
Our Environment Class 10 Science Notes pdfOur Environment Class 10 Science Notes pdf
Our Environment Class 10 Science Notes pdf
 
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
 
Economic Importance Of Fungi In Food Additives
Economic Importance Of Fungi In Food AdditivesEconomic Importance Of Fungi In Food Additives
Economic Importance Of Fungi In Food Additives
 
Details on CBSE Compartment Exam.pptx1111
Details on CBSE Compartment Exam.pptx1111Details on CBSE Compartment Exam.pptx1111
Details on CBSE Compartment Exam.pptx1111
 

fever-presentation (1).ppt

  • 1. Fever National Pediatric Nighttime Curriculum Written by Debbie Sakai, M.D. Institution: Lucile Packard Children’s Hospital
  • 2. Case 1  4-month-old well-appearing girl admitted for croup and respiratory distress. Develops fever to 39.1. What additional evaluation would you do at this point?
  • 3. Case 2  12-year old boy with AML, in induction, admitted for febrile neutropenia. He had just received his first dose of ceftazidime and vancomycin when he developed another fever to 38.5, chills, and new dizziness shortly after receiving the antibiotics. What would be the next steps in this patient’s management?
  • 4. Objectives  To determine which patients are at high risk of developing sepsis.  To assess patient with fever.  To initiate empiric therapy.
  • 5. Objectives  To determine which patients are at high risk of developing sepsis.  To assess patient with fever.  To initiate empiric therapy.
  • 6. Which patients are high-risk for sepsis?  Neonates  Transplant recipients Bone marrow Solid organ  Oncology patients Undergoing therapy, mucositis, central line Most chemotherapy: nadir ~ 10 days after rx  Asplenic patients, including sickle cell
  • 7. Definition of fever  38.0  Neonates (< 12 months)  Any immunocompromised patient  Including transplant patients, patients with immunodeficiencies, oncology patients (sustained ≥38 x 1 hour)  38.5  All other patients  These are general guidelines, individual patients/services may have different parameters
  • 8. What etiologies cause fever?  Infectious  Inflammatory  Oncologic  Other: CNS dysfunction, drug fever  Life-threatening conditions
  • 9. Infectious  Systemic  Bacteremia, sepsis, meningitis, endocarditis  Respiratory  URI, sinusitis, otitis media, pharyngitis, pneumonia, bronchiolitis  Abdominal  Urinary tract infection, abscess (liver, kidney, pelvis)  Bone/joint infection  Hardware infection  Central line, VP shunt, G-tube
  • 10. Inflammatory  Kawasaki disease  Juvenile inflammatory arthritis  Lupus  Inflammatory bowel disease  Henoch-Schonlein purpura
  • 12. Life-threatening conditions  Sepsis, febrile neutropenia  Vital sign instability, poor-perfusion, may have altered mental status, disseminated intravascular coagulation  Hemophagocytic lymphohistiocytosis  Splenomegaly, bicytopenia, elevated ferritin, elevated triglycerides, low fibrinogen, hemophagocytosis, low/absent NK cell function, elevated soluble IL2 receptor  Malignant hyperthermia  Following administration of inhaled anesthetics or depolarizing neuromuscular blockers (succinylcholine), at-risk patients include those with myopathy  Muscle rigidity, rhabdomyolysis, acidosis, tachycardia
  • 13. Objectives  To determine which patients are at high risk of developing sepsis.  To assess patient with fever.  To initiate empiric therapy.
  • 14. Assessment  Vital signs  Repeat physical exam  Overall appearance (sick, toxic)  Central/peripheral lines  Incisions/wounds  VP shunt/tracheostomy/gastrostomy tube  Oral mucosa/perineal area for neutropenic patients  Perfusion  Call for help if concerning vital signs/exam  Fellow or attending  Rapid response team (RRT)/PICU
  • 15. Laboratory evaluation  What would you do if the patient has hardware (VP shunt, tracheostomy, gastrostomy tube) or central line? CBC with differential Blood culture CSF (tap VP shunt)
  • 16. Laboratory evaluation  What would you do if the patient has a high risk for sepsis? Immunocompromised Transplant recipient Oncology patient CBC with differential Blood culture Urinalysis and urine culture
  • 17. Laboratory evaluation  What would you do for an infant ≤ 2 months of age? CBC with differential Blood culture Catheterized urinalysis and urine culture Lumbar puncture
  • 18. Laboratory evaluation  Who needs a urinalysis and urine culture? Circumcised males < 6 months Uncircumcised males < 1 year Females < 2 years Immunocompromised patients Patients with history of UTI/pyelonephritis
  • 19. Laboratory evaluation  Who needs a lumbar puncture?  Neonates ≤ 2 months  Ill-appearing  Altered mental status  What tests do you send?  Gram stain and culture  Cell count and differential  Protein and glucose  Extra tube for additional studies  Enteroviral PCR, HSV PCR, CA encephalitis project
  • 20. Laboratory evaluation  Consider CRP, ESR  Consider PT/PTT, fibrinogen  Consider chest x-ray  Consider nasopharyngeal DFA  For immunosuppressed patients consider: Viral PCR studies (ie CMV, EBV, HHV6) Additional imaging (ie ultrasound, CT scan)
  • 21. Objectives  To determine which patients are at high risk of developing sepsis.  To assess patient with fever.  To initiate empiric therapy.
  • 22. Treatment for non-high risk patients  May not need empiric antibiotics  Consider the following issues: Is patient clinically stable? Are the screening laboratory studies suggestive of infection?
  • 23. Treatment for patients with central lines  Ceftriaxone  Vancomycin
  • 24. Treatment for neonates ≤ 2 months  If < 28 days old Ampicillin AND cefotaxime OR Ampicillin AND gentamicin  Consider acyclovir  If 29-60 days old Ceftriaxone ± Ampicillin OR Vancomycin Until CSF results are known (cell count, protein, glucose), initiate therapy with meningitic dosing regimen
  • 25. Treatment for febrile neutropenia  Broad-spectrum antibiotics with Pseudomonas coverage  Ex: use ceftazidime or piperacillin-tazobactam  Consider double coverage for possible resistant Pseudomonas  Ex: add amikacin or tobramycin  Consider gram-positive coverage (central line, skin infections)  Ex: add vancomycin  Consider anaerobic coverage (mucositis, typhlitis)  Ex: use piperacillin-tazobactam or add clindamycin
  • 26. Take home points  Infections are the most common cause of fever in children  During assessment of a child with fever, pay close attention to vital sign changes, overall appearance, and potential sites of infection  Closely monitor for clinical decompensation after antibiotic administration, particularly in patients at high-risk of developing sepsis
  • 27. References  Baraff LJ. Management of fever without source in infants and children. Ann Emerg Med. 2000. 36:602-14.  Meckler G, Lindemulder S. Fever and neutropenia in pediatric patients with cancer. Emerg Med Clin N Am. 2009. 27:525-44.  Palazzi EL. Approach to the child with fever of unknown origin. UpToDate. 2011  Palazzi DL. Etiologies of fever of unknown origin. UpToDate. 2011.  Tolan R. Fever of unknown origin: A diagnostic approach to this vexing problem. Clin Pediatr. 2010;49:207-13.